ROS-1 NSCLC therapy resistance mechanism
Miguel García-Pardo(Hospital Universitario Ramón y Cajal), Antonio Calles(Dana-Farber Cancer Institute)
Cited by 17
Related Papers
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
|Journal of Thoracic Oncology|2015|290
Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study
|Clinical Cancer Research|2018|125
Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
|British Journal of Cancer|2022|112
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)
|Journal of Thoracic Oncology|2022|97